Immunotherapies for CLL Complement Targeted Agents – Clinical Oncology News
Clinical Oncology News |
Immunotherapies for CLL Complement Targeted Agents
Clinical Oncology News Consistent with previously published evidence that prior ibrutinib (Imbruvica, Pharmacyclics) therapy improves engraftment of chimeric antigen receptor (CAR) T cells in patients with CLL (Blood 2016;127[9]:1117-1127, PMID: 26813675), preliminary … |
